Full year and Q4 2021 results

1 9 February 2022 Full year and Q4 2021 resultsCautionary statement regarding forward-looking anticipate , estimate , expect , intend , will , project , plan , believe , target ,theseincludestatementsrelatingtofuturea ctions,prospectiveproductsorproductappro vals,futureperformanceorresultsofcurrent andanticipatedproducts,salesefforts,expe nses,theoutcomeofcontingenciessuchaslega lproceedings, (includingundertheMarketAbuseRegulations ,UKListingRulesandtheDisclosureGuidancea ndTransparencyRulesoftheFinancialConduct Authority),theGroupundertakesnoobligatio ntoupdateanyforward-lookingstatements,wh etherasaresultofnewinformation, ,however,consultanyadditionaldisclosures thattheGroupmaymakeinanydocumentswhichit publishesand/orfileswiththeUSSecuritiesa ndExchangeCommission(SEC).Allinvestors,w hereverlocated, , ,inherentrisksanduncertainties,manyofwhi chrelatetofactorsthatarebeyondtheGroup ,includingthoseinthispresentation, ,butarenotlimitedto, Riskfactors intheGroup , ,targets,ambitionsandexpectationsregardi ngfutureperformanceandthedividendshouldb ereadtogetherwiththesection Basisofpreparation,assumptionsandcaution arystatements onpages5-7ofourstock-exchangeannouncemen trelatingtoanupdatetoinvestorsdated23 June2021andthe Guidance,assumptionsandcautionarystateme nts , , progressQ&AFinancial results and 2022 guidanceGrowth driversEmma WalmsleyLuke MielsDeborah WaterhouseBrian McNamaraIain MackayRoger ConnorDavid Redfern3R&D updateDr Hal BarronAcceleratingprogressEmma Walmsley42021: strong results and accelerating momentum5 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise.

2 1. Actual exchange rate 2. Excluding COVID-19 solutions 3. At constant exchange rates or CER 4. Excluding brandsdivested/under review. All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the section Guidance, assumptions and cautionary statements on pages 62 and 63 of our full year and fourth quarter 2021 earnings release. All outlook and ambition statements are given ona constant currency basis and use 2021 actual exchange rates as a base, assuming a continuation of Q1 2021 closing rates. Compound annual growth rate is for the five years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and includeanticipated sales of new products and life-cycle innovation launched from 2021 onwards. Note: COVID-19 solutions are excluded from the % mAER1 CERT urnover34,114-5 Total operating profit6,201(20)(9)Total (24)(13)Adj. operating profit8,806(1)9 Adj.

3 (2)9 Free cash flow4,437(18)n/a2022: step change in growth for new GSKFull-year 2022 guidance2,35-7% sales growth12-14% adj. operating profit growthKey highlights Turnover: 34 billion (+5%), with targeted R&D investment, support for new and ongoing launches, and continued cost optimisation Strong business momentum: Pharmaceuticals +10% (incl. New and Specialty +26%), Vaccines +2%, Consumer +4%4 Adj. operating profit: 9 billion (+9%) Adj. EPS: (+9%) R&D pipeline: three major product approvals in 2021 with multiple late-stage milestones in 2022-23 New Consumer Healthcare: Capital Markets Day on 28 February 2022 followed by demerger in mid-2022 Full-year 2021 performanceExceeded raised guidance:Adj. EPS stable2,3 Excellent progress across all three strategic priorities6 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise. 1. Messenger ribonucleic acid 2.

4 Business development 3. Long acting 4. Human immunodeficiency virus 5. Life-cycle innovation 6. Hypereosinophilicsyndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), chronic rhinosinusitis with nasal polyposis (CRSwNP) nephritis (LN)8. Binding agreements and doses reserved through other agreements to be supplied over 2021-20229. Excluding brands divested/under carbon and nature environmental commitments to 2030 Unconstrained capacity tosupportrecord Shingrixsales in2022 Daprodustat met all primary endpoints in phase III programmeNew and Specialty +49% Q4, +26% FY (+14% FY ex-Xevudy)InnovationPerformanceCultureAm bition to positivelyimpact health of > bn people over 10 yearsInvestment inmRNA1capabilities and BD2tostrengthen pipeline#1 in Dow Jones Sustainability, Access to Medicine IndicesConsumer Healthcaresales9acceleration+11% Q4, +4% FYSuccessful LCI5with new indications forNucala6and Benlysta7 Xevudyc. 1bn FY sales; agreements8for > doseswith delivered in 2021 TrustExciting pipeline of 64 vaccines and medicines, 22 in pivotal studiesCabenuva, Apretudepioneer LA3approachtoHIV4medicineReady to unlock long-term value with the demerger in mid-20227 Step change in long-term growthA new GSK with new ambitionsWe unite science, talent and technology to get ahead of disease togetherOn track to demerge world-leading Consumer Healthcare businessStrengthen new GSKbalance sheetMaximise shareholder value28 February 2022: new Consumer Healthcare, virtual Capital Markets DayUnlock potential in new GSK and new Consumer Healthcare>5%Sales CAGR, 2021-2026>10%Adj.

5 Operating profit CAGR, 2021-2026> 33bnSales ambition, 2031 All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with thesection Basis of preparation, assumptions and cautionary statements on pages 5-7 of our stock exchangeannouncement relating to an update to investors dated 23 June 2021 and the Guidance, assumptions and cautionary statements on pages 62 and 63 of our full year and fourth quarter 2021 earnings release. All outlook and ambition statements are given ona constant currency basis and use 2021 actual exchange rates as a base, assuming a continuation of Q1 2021 closing rates. Compound annual growth rate is for the five years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and includeanticipated sales of new products and life-cycle innovation launched from 2021 onwards. Note: COVID-19 solutions are excluded from the drivers Luke MielsDeborah Waterhouse Brian McNamara 8025507510 012 5 NucalaNew and Specialty: strong double-digit growth(+26%, +14% ex-Xevudy)9 Nucala: 1,142m, +22% Trelegy: 1,217m, +57% Oncology: 489m, +37% Benlysta: 874m, +29% Quarterly sales progression ( m)7 Maintained double-digit growth (+22% in Q4) Use of biologics in SLE8and LN accelerating(+23% vs 20209) benefiting Benlysta as leader SC10formulation and launches in LN driving new patient growth China: inflection since NRDL11with new patients in 2021; LN decision early 2022 Blenrep: FY sales of 89m (+185%) driven by non-academic setting in US Zejula: strongest quarter to date ( 108m, +24%) despite ongoing impact of COVID-19 Jemperli^: expanded footprint in US and Europe.

6 Pan-tumour dMMR+12approval supports future developmentIL-5 Competitor Sustained momentumacross year (+53% in Q4) Dual indication driving demand in US and Japan Global leader (71% share3) despite growing competition 88% US share, with leading share of voiceinPCPs4and specialists5 Leading IL-5 biologic foreosinophil-led diseases At home admin for patient, healthcare practitioner flexibility New indications to support future growth US: NP further differentiates EMA: approval for HES, EGPA, CRSwNP China: first biologic approval for EGPAB lenrepZejulaJemperliMarket shares (MQT2) in IL-5 inhibitors62021 Quarterly oncology sales ( m)7Q1Q2Q3Q1Q2Q3Q4201820202021+22%+35%+34 %+25%+23%+13%+15%+24%+24%+35%+25%+15%+21 %+29%+31%+33%Q4 Competitor ETrelegyCompetitor C + Competitor C Gx + Competitor DAdvair+ AdvairGx + Competitor D53%13%7%Share of US triple therapy patients (COPD1)20%10 %20 %30 %40 %50 %60 %Jan-20 Mar-20 May-20 Jul-20 Sep-20 Nov-20 Jan-21 Mar-21 May-21 Jul-21 Sep-21 Nov-212019+25+34%+35%7006005004003002001 00 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise.

7 1. Chronic obstructive pulmonary disorder 2. IQVIA IQ2021w/e 11/26/2021 3. IQVIA -TRxweekly data w/e 12/31/2021 4. Primary care physicians 5. IQVIA SMART Promotional Insights Database 6. MQT Nov 2021 for all except US (MQT Dec 2021) 7. GSK Quarterly Reports 8. Systemic lupus erythematosus 9. Based on sales and real-time quantitative surveys across US, EU5, Japan and China 10. Subcutaneous 11. National Reimbursement Drug List 12. Deficient Mismatch Repair ^ : Shingrix poised for 2022 recovery10 Shingrixsequential growth3in 2021 underpins recovery trajectory010 020 030 040 050 060 0Q1Q2Q3Q4 Sales ( m)+70%+19%InternationalEuropeUS2021: Shingrixsales 1,721m, -9% US: strong sequential growth from Q2 to Q4 driven by increased non-retail use following initial COVID-19 vaccination disruption EU: driven by new launches in Italy, Spain, UK, Finland, Denmark, Austria and strong growth in Germany Unconstrained supply: available in 17 countries and 9 new launches planned in 2022, expanding to 35 markets by 2024 LCI geared to expand adult indications, liquid presentation2022 outlook Expect record year for sales, withstrongdouble-digit growth Key driver of expected low teens per centvaccinessales growth1 Confident in ambition to double Shingrixsales by 20262 Absolute values at actual exchange rates.

8 Changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise. 1. Excluding pandemic adjuvant sales 2. Ambition uses 2020 base. 3. Growth at : innovation medicines1accelerating growth11 Dovato driving momentum across all regionsAbsolute values at actual exchange rates; changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise. 1. Innovation medicine sales comprise,Cabenuva,Dovato,Rukobia, andJuluca2. Assumes paediatric exclusivity on growth targets Best-in-class two-drug regimen Sales more than doubled in 2021 to 787m, reaching 16% of total HIV sales Dolutegravir based regimens in switch across US/EU On track to deliver 1bn of sales in 2022 with significant further growth potential Patent protection to at least 2028 US/2029 EU20. 00. 51. 01. 52. 02. 53. 03. 54. 0020 040 060 080 01, 0 001, 2 001, 4 001, 6 00 Innovation sales ( m)2020 HIV sales growth%20192021 HIV GrowthJulucaRukobiaDovatoCabenuvaHIV: shifting the paradigm towards long-acting regimens12 Encouraging launch forApretudeMomentum building behind Cabenuva US two-monthly dosing approved Treatment dosing days reduced from 365 to six >4,500 people living with HIV taking Cabenuva First mover advantage with anticipated five-years head start over competition LA injectable treatment category expected to reach 4-5bn Patent protection extends through 2031 1st LA Injectable for PrEP1, dosed every two months Approved by US FDA on 20 December 2021 Superior to daily oral standard of care Reduces stigma, adherence issues of daily oral therapy Positive initial feedback from patients and prescribers US political will to end epidemic LA injectable PrEPmarket expected to reach c.

9 4-5bnLong-acting regimens expected to generate c. 2bn in sales by 2026 ( of total HIV sales)1. Pre-exposure prophylaxis. All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the section Basis of preparation, assumptions and cautionary statements on pages 5-7 of our stock exchangeannouncement relating to an update to investors dated 23 June 2021 and the Guidance, assumptions and cautionary statements on pages 62 and 63 of our full year and fourth quarter 2021 earnings release. All outlook and ambition statements are given ona constant currency basis and use 2021 actual exchange rates as a base, assuming a continuation of Q1 2021 closing rates. Compound annual growth rate is for the five years to 2026, using 2021asthe base year. Pipeline sales are risk-adjusted and includeanticipated sales of new products and life-cycle innovation launched from 2021 onwards. Note: COVID-19 solutions are excluded from the leader in Consumer HealthcareFull-year 2021 +4%1sales growth despite -1% headwind from cold and flu13 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for the full year (FY) 2021, unless stated otherwise.

10 1. Excluding brands divested/under review. 2. Proforma sales growth 2019-2021 excluding brand divested/under review. All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the section Guidance, assumptions and cautionary statements on pages 62 and 63 of our full year and fourth quarter 2021 earnings business momentum Q4 2021 +11%1 New Consumer Healthcare expectsto deliver superior growthStrong category performance despite the adverse impact of COVID-19 on respiratory health+4%Organic sales growthCAGR, 2019-20212+4-6%medium-term annualorganic sales growthGrowth % mAERCEROral health2,732(1)5 Pain relief2,27637 Vitamins, minerals & supplements1,512-4 Respiratory health1,133(6)(1)Digestive health & others1,803(1)4 Continuing sales19,456(1)4E-commerce of total; up mid-20%-971011-10-5051015Q4 2021 Growth % CERQ1 2021Q2 2021Q3 2021 GrowthDelivering superior growth and attractive sustainable returnsCategory-leading brands and geographic outlookGlobal scale, innovation capabilities, digital, and operationsCapital allocationFocus on driving free cash flowPriorities for capital investmentDividend policyCreating a world-leader in Consumer HealthcareWorld-class portfolio, category-leading brands and global scale14 StrategyNew Consumer Healthcare purpose, strategy, and cultureResponsible business integralto all we doIntroducing the leadership team28 February 2022.